Loading
Cheap generic versions of targeted cancer drugs like imatinib exist, but patients with rare tumours carrying the matching mutation often cannot get them. A structured programme would treat them and collect the evidence.
The Netherlands' Drug Rediscovery Protocol (DRUP) gives patients with actionable mutations access to approved targeted drugs outside their label, with cohorts expanding on response and payers covering successful cohorts; it has been replicated in several countries. Now that imatinib, erlotinib, gefitinib, sunitinib, abiraterone and others are generic, an analogous protocol for generic targeted drugs would be extremely cheap. The proposal is a DRUP-generic arm run across countries including middle-income ones, with genomic profiling, cohort-based Simon two-stage designs, and pre-agreed payer coverage for cohorts meeting response thresholds.
Shares Basket, umbrella, and platform trials, No incentive to repurpose cheap drugs, Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs.
Shares Netherlands Cancer Institute (NKI-AvL), No incentive to repurpose cheap drugs, Rare and paediatric cancers without markets.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs.